Introducing the TruTumor platform
Meeting an industry need.
Given the high failure rate of new anti-cancer therapies in late-stage clinical trials, better preclinical models that better represent in vivo human tumors are needed.
Most of the complex tumor models that have been utilized in recent years by the industry, e.g., tissue slices and xenogeneic transplants, attempt to replicate the complexities of the tumor microenvironment but are not yet suitable for routine research or clinical use. These model systems have limitations such as low sample analysis throughput, limited culture duration, poor reproducibility, and have not demonstrated clinical validity. Researchers need a tumor testing platform that proves:
- High throughput
- Flexible in measurement capability
And most importantly… has demonstrated clinical utility as representative of the patient
TruTumor patient primary tumor culture assay
TruTumor is based on a proprietary, clinically validated primary tumor cell culture assay that has proven clinical utility as a predictive and prognostic drug response maker. Together, with access to thousands of well-characterized tumor cell lines, it addresses heterogeneity both with and between tumors.
This platform has been developed and refined in over 15 years of internal research and development and is protected by trade secrets and more than 20 issued patents.
Analyze tumor cells and what they shed:
Demonstrated clinical utility as a predictive and prognostic drug response biomarker
The clinical test (known as ChemoFX™) has demonstrated clinical utility in GYN cancers. The TruTumor research platform is available for all tumor types.
ChemoFX is associated with a 50% improvement in progression-free survival and a 14-month improvement in overall survival when patients receive a sensitive therapy.
Patients treated with a sensitive agent identified by ChemoFx lived 2.5x longer than patients treated with a resistant agent.
ChemoFx identifies potentially effective treatments for the majority (59%) of Platinum-Resistant Patients.
Measuring drug response in primary tumor cultures
Helomics has extensive data from clinical testing on tumor drug response to standard-of-care drugs. Drug response is evaluated using standard dose-response-metrics (AUC7, IC50, EC50) using an imaging endpoint assay.